Akademik Veri Yönetim Sistemi
Turk Anesteziyoloji ve Reanimasyon, cilt.27, sa.8, ss.406-410, 1999 (Scopus)
The aim of this study was to evaluate the effects of IM piroxicam supplement with meperidine administered via IV-PCA for postoperative pain treatment on the basis of consumption of meperidine, postoperative pain score, demand/delivery ratio, sedation score, hemodynamic and side effects. Fourty ASA class I-II patients who underwent total abdominal hysterectomy were included in this study. Patients were randomly divided into two groups after the induction of anaesthesia. In Group I, 2 mL (40 mg) piroxicam IM (Felden, Pfizer) and in Group II, 2 mL of normal saline solution was administered after the induction of anaesthesia. All of the patients received meperidine in a setting of 0.5 mg/kg loading dose, 2 mg/h basal infusion rate, 5 mg dose of PCA bolus, 15 min lock out time and 50 mg of 4 h limit via IV-PCA machine (Abbott Pain Management Provider TM) just after cooperation and evaluation of pain score with visual analogue scale (VAS) at the end of the operation. Patients were monitorized for consumption of meperidine, demand/delivery ration, VAS, sedation score, SpO2, SAP, DAP and HR for 24 h. We observed that IM piroxicam supplement to meperidine administered via IV- PCA decreased the VAS score, demand/delivery ratio, consumption of meperidine and frequency of nausea and vomitting. In addition there was no severe complication related to the procedure. As a result, we concluded that IV piroxicam can be a safe supplement to the meperidine given via IV-PCA for postoperative analgesia to increase effectiveness and to decrease consumption of meperidine frequency of side effects.